Press Releases

AI Therapeutics announced the start of Phase II clinical trial for the treatment of newly diagnosed COVID-19 patients in collaboration with Yale University. AI Therapeutics is a biopharmaceutical company that develops novel therapies identified through a proprietary artificial intelligence algorithm for matching drugs to new indications (Guardian Angel™). The randomized, double-blind, placebo-controlled study (NCT04446377) will enroll up to 142 outpatients to evaluate the safe

BlueAllele, a biotechnology company focused on enhancing the quality and precision of gene editing systems for patients with genetic diseases, announced the launch of PALIDON™, an innovative and proprietary repair template technology. Many rare genetic diseases are caused by mutations within a single gene. However, the location of the mutation often varies for different individuals with the same disease. Conventional gene editing approaches are primarily limited to correcting

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company developing a pipeline of novel T cell therapies for patients suffering from cancer, announced that the Company plans to discuss initial data from the Phase 1 portion of the TC-210 Phase 1/2 clinical trial for patients with mesothelin-expressing solid tumors in a premarket press release and webcast to be held on Monday, July 27th, 2020. The Company will host a conference call and webcast with a slide presentation at 8:00a

Ultivue , Inc. announced a collaboration agreement with OracleBio that will help gain greater insight and advance personalized tumor characterization in translational and clinical cancer research and development. of drugs by multiple immunofluorescence staining and image analysis. The agreement connects OracleBio's histopathology image analysis expertise and Ultivue's tissue staining capabilities with the goal of providing pharmaceutical companies with a comprehensive workfl

G1 Therapeutics, Inc., a clinical-stage oncology company, announced a license agreement for lerociclib to EQRx™, a biopharmaceutical company focused on making innovative medicines at dramatically lower prices for the benefit of people and society. Under the terms of the agreement, EQRx gains exclusive rights for lerociclib in the U.S., Europe, Japan and all other global markets, excluding the Asia-Pacific region (except Japan). G1 will receive an upfront cash payment of $20 million and

Talaris Therapeutics, Inc., a privately held biotechnology company developing transformative cell therapies that have the potential to induce durable immune tolerance across a range of indications, announced that the first patient has been dosed in the FREEDOM-1 Phase 3 clinical trial of FCR001 in living donor kidney transplant (LDKT) recipients. The trial will evaluate the safety and efficacy of a single dose of FCR001, the company’s investigational cell therapy designed to durably fre

Qualigen Therapeutics, Inc. announced the signing of an exclusive worldwide license agreement with the University of Louisville (UofL) for the intellectual property covering the "RAS-F" family of RAS oncogene protein-protein interaction inhibitor small molecule drug candidates. Qualigen will evaluate these patent-pending compounds in order to identify a lead drug candidate for further development against one or more cancers. This license agreement builds upon the Company&#

Staten Biotechnology B.V. announced the initiation of dosing of the Company’s lead asset, STT-5058, in a First-in-Human clinical study. STT-5058 is a monoclonal antibody that targets the lipoprotein ApoC3 and is being developed in collaboration with Novo Nordisk. Staten Biotechnology and Novo Nordisk entered a collaboration and exclusive option agreement in December 2018 to develop novel therapeutics for the treatment of dyslipidaemia. Novo Nordisk is providing funding and sup

Life Science Newswire – Arctoris Ltd. supports global research efforts to find new therapeutics against COVID-19. Scientists in academic centres and companies around the world desperately search for novel therapeutics and vaccines to treat and prevent COVID-19. However, with lockdowns and limited access to laboratories, researchers are being forced to work from home, putting research continuity at risk. To help scientists continue their life-saving R&D, and ensur

AbCellera announced that it has entered into an agreement with Alloy Therapeutics to use the ATX-Gx™ humanized mice platform to enable best-in-class in vivo human antibody discovery for its partner programs. Under the terms of the agreement, AbCellera will offer its biotech and pharma partners access to ATX-Gx™, Alloy’s proprietary suite of immunocompetent transgenic mice, for use in any antibody discovery program and against any therapeutic target. Mice that produ